Home > Analytics > PIRAMAL PHARMA

PIRAMAL PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 543635     NSE : PPLPHARMA    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : NA
May 03,2024
Price(EOD): ₹ 151.10
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 19,989.02 Cr
Value of ₹ 1 Lac invested in PIRAMAL PHARMA
on Oct 19,2022 (price: ₹ 187.27)

₹ 1 L

₹ 0.81 L

1W : 6.2% 1M : 16.4% 1Y : 106.8%
COMMUNITY POLL
for PIRAMAL PHARMA
Please provide your vote to see the results
PIRAMAL PHARMA is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Best 1M Momentum Small Cap Stocks
Industry Peers & Returns1W1M1Y
PIRAMAL PHARMA 6.2% 16.4% 106.8%
SUN PHARMACEUTICAL INDUSTRIES 0.3% -7.5% 53.9%
CIPLA 1.1% -4.8% 56.4%
DR REDDYS LABORATORIES 1.6% 1.6% 27.6%
ZYDUS LIFESCIENCES 5.2% -0.2% 90.1%
DIVIS LABORATORIES -1.9% 10.7% 21.4%
MANKIND PHARMA -2.3% 0.1% NA
TORRENT PHARMACEUTICALS 1.6% 2% 61.8%
LUPIN 2.4% 2% 132.5%

FUNDAMENTAL ANALYSIS OF PIRAMAL PHARMA

 
Fundamentals Score
[ Q(TTM): Dec2023, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF PIRAMAL PHARMA

 
Valuation Score
[As on : May 03,2024 ]

Ratio Consolidated
P/E
P/B
P/S
-225.69
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -88.57 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

2.95
P/B Calculated based on Book Value of Rs 6,773.50 Cr
[Latest Year - Mar2023 - Consolidated Results ]

2.57
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 7,782.38 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 12% undervalued companies ! Discover More →

FAIR VALUE OF PIRAMAL PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
NA
3122%
102%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF PIRAMAL PHARMA


Insights 💡 PPLPHARMA is one of the top 71% companies with bullish price momentum currently! Discover More →

PIRAMAL PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF PIRAMAL PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2023
2022
2021
Avg_3yrs
0.31
0.23
0.04
0.19
0.81
0.6
0.52
0.64
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF PIRAMAL PHARMA

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF PIRAMAL PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
2.47%
1.03%
-73.55%
72.75%
14.14%
207.31%
106.06%
96.37%
QtrlyTrend
6
Latest Qtr: Dec2023
Quarterly Result Analysis →


PIRAMAL PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE 400 MIDSMALLCAP 1.7% 8% 61.5%
S&P BSE MIDSMALLCAP 1.4% 8.6% 66.5%
S&P BSE HEALTHCARE 0.8% 1.5% 55.8%
S&P BSE 500 0.5% 3.2% 37.9%
S&P BSE ALLCAP 0.4% 3.7% 40%
NSE Indices1W1M1Y
NIFTY MID SMALL400 1% 7.8% 63.4%
NIFTY500 MULTICAP 50:25:25 0.6% 5.2% 47.8%
NIFTY 500 0.4% 3.5% 39%
NIFTY SMALLCAP250 0.3% 10.2% 69.8%
NIFTY FREE SMALL 100 0.3% 10.9% 76.6%

You may also like the below Video Courses


FAQ about PIRAMAL PHARMA


Is PIRAMAL PHARMA good for long term investment?

As on May 03,2024, the Fundamentals of PIRAMAL PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of PIRAMAL PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is PIRAMAL PHARMA UnderValued or OverValued?

As on May 03,2024, PIRAMAL PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of PIRAMAL PHARMA ?

As on May 03,2024, the Intrinsic Value of PIRAMAL PHARMA is Rs. 39.69 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. -24.57
Fair Value [Median EV / Sales Model] : Rs. 4.69
Fair Value [Median Price / Sales Model] : Rs. 74.69
Estimated Median Fair Value of PIRAMAL PHARMA : Rs. 39.69

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is PIRAMAL PHARMA trading at a Premium or Discount?

As on May 03,2024, PIRAMAL PHARMA is trading at a Premium of 281% based on the estimates of Median Intrinsic Value!